AG
RUBY

Aperio Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

Aperio Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$179K Buy
23,550
+3,622
+18% +$21.5K ﹤0.01% 2325
2020
Q3 		$100K Sell
19,928
-4,016
-17% -$21.3K ﹤0.01% 2322
2020
Q2 		$143K Buy
23,944
+12,527
+110% +$73.9K ﹤0.01% 2237
2020
Q1 		$51K Buy
+11,417
New +$84.8K ﹤0.01% 2278

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aperio Group's RUBY Position: Q4 2020 in Review

Aperio Group increased its Rubius Therapeutics, Inc (RUBY) stake by 18% in Q4 2020, buying an estimated $21.5K and bringing the position to 23,550 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #2325.

Aperio Group first reported a position in RUBY in Q1 2020 and has held it in 4 quarters since. 87 funds tracked by Wall St. Rank hold RUBY as of Q4 2020.

  • Aperio Group held 23,550 shares of Rubius Therapeutics, Inc worth $179K as of Q4 2020.
  • Aperio Group bought 3,622 Rubius Therapeutics, Inc shares in Q4 2020, an estimated $21.5K.
  • Rubius Therapeutics, Inc made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2325 holding.
  • Aperio Group first reported a position in Rubius Therapeutics, Inc in Q1 2020 and has held it in 4 quarters since.
  • 87 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.